Sentinel in anatomy Banner

Cost of stroke

Every stroke matters, protect the brain

TAVI related stroke apart from its devastating clinical impact, also adds a considerable economic burden to the healthcare system, patients and society.

Brain Icon and costs titles

Healthcare costs

Drug costs

  • Pharmacological therapies

 Hospital care costs

  • Stroke unit/neurology
  • Length of stay
  • Imaging and lab tests
  • Medical consultation
  • Inpatient rehabilitation

Other costs

  • Readmissions
  • Rehabilitation
  • Outpatient care
  • Nursing homes

Societal costs

Productivity loss due to morbidity

  • Work absence
  • Disability

 Productivity loss due to death

  • Workloss due to early mortality

Informal care

  • Informal, unpaid caregivers

With impact from short to long term…

Short-term costs

Short term costs Icons

Acute Severe Ischemic Stroke Management Cost in Western Europe1

Mean in-hospital cost per patient*is 8.000€ - 14.000€

3 times longer Lenght of Stay (LOS) for patients with disabling stroke2,3

 

Mid to long-term costs

Medium long term costs Icons

Social and economic costs per patient** in the first-year post-event4-11

Up to 66.000€

Disabling stroke leads to..

9 times higher Direct Healthcare Costs in the first 3 three months after discharge5

5 times higher Productivity Losses and Informal Care Costs10

 

…and with a large societal footprint

Fifty three percent Icon

Healthcare Costs

  • Hospital Care Cost
  • Nurse/GP Visits
  • Outpatient Care
  • Readmissions
  • Nursing Homes

 

Twenty seven percent Icon

Informal Care

  • Informal, unpaid caregivers

 

Twenty percent Icon

Loss of Productivity

  • Work absence
  • Disability
  • Work los due to early mortality

 

While the benefit of CEP can be considerable

66k

TAVI procedures

Performed in EU Big5 in 2021

 

900

Disabling strokes after TAVI

Without CEP

+500

Disabling strokes avoided*

If SENTINEL CPS had been used in TAVI patients 

OVER €30 M

Healthcare and social costs avoided

Only in the first-year post event if patients had been benefitting from SENTINEL CPS

 

TAVI related stroke occurrence estimate in EU Big 5 countries 

UK

UK

~6,700 TAVI procedures performed in 2021

Which could result in...

~ 90 disabling strokes after TAVI without CEP

~33 disabling strokes avoided* If SENTINEL CPS had been used in TAVI patients

Germany

Germany

~26,800 TAVI procedures performed in 2021

Which could result in...

~360 disabling strokes after TAVI without CEP

~134 disabling strokes avoided* If SENTINEL CPS had been used in TAVI patients

France

France

~16,900 TAVI procedures performed in 2021

Which could result in...

~230 disabling strokes after TAVI without CEP

~85 disabling strokes avoided* If SENTINEL CPS had been used in TAVI patients

Italy

Italy

~10,000 TAVI procedures performed in 2021

Which could result in...

~140 disabling strokes after TAVI without CEP

~50 disabling strokes avoided* If SENTINEL CPS had been used in TAVI patients

Spain

Spain

~5,700 TAVI procedures performed 2021

Which could result in...

~80 disabling strokes after TAVI without CEP

~29 disabling strokes avoided* If SENTINEL CPS had been used in TAVI patients

Icon with Browser

Explore EDUCARE online

Register to customize your learning journey with free online education courses and in-person training events in your medical specialty.

Go to EDUCARE
Ask a question icion

Talk to a representative

Want to learn more about products and services? One of our sales representatives will be happy to contact you.

Ask a representative

Wilkins, E, et al. European Cardiovascular Disease Statistics 2017. Brussels: European Heart Network; 2017.
The picture shows the breakdown of Healthcare and Societal costs of stroke (assessed in 2017) reported in The Burden of Stroke in Europe report conducted by King’s College London for the Stroke Alliance for Europe (SAFE).

*Index hospitalization includes the cost of drugs, imaging and laboratory exams, bed, staff, medical procedures, consultation visits, inpatient rehabilitation.

**Direct healthcare costs following discharge include the costs of rehabilitation, outpatient visits, institutionalization costs and drugs. Direct non-healthcare costs include social services (residence in nursing home or other healthcare centers/domiciliary care), other non-healthcare costs such as adapted medical transport and physical adaptations, informal care (long-term care provided by unpaid family members, or an informal caregiver). Productivity losses: societal costs associated with reduced work productivity, incapacity for work, occupational disability, premature death.

1. Wilson et al. Eur Stroke J. 2017 Mar;2(1):3-12; DRG tariffs associated with Acute disabling stroke management in EU Big5.

2. Caro et al. Stroke. 2000 Mar;31(3):582-590. 3. Jørgensen et al. Stroke. 1997 Jun;28(6):1138-41.

3. Grieve et al. Stroke. 2001 Jul;32(7):1684-91.

4. Baeten et al.  Cost Effectiveness and Resource Allocation : C/E 8 (2010): 21 - 21. 5. Fattore et al. BMC Neurol 12, 137 (2012).

6. https://www.nice.org.uk/guidance/ng196/evidence/g2-anticoagulant-therapy-health-economics-analysis-pdf-9081923443.

7. Spieler et al. Cerebrovasc Dis. 2004;17(2-3):134-42.

8. de et al. Eur Stroke J. 2017 Sep;2(3):272-284.

9. Alvarez-Sabín, et al. Eur J Health Econ 18, 449–458 (2017).

10. Barral et al. European Journal of Neurology, 2020, 28(2):548-557.

11. Willers et al. Plos one, 2017, 12(4):e0174861.

Costs displayed in Euro adjusted to 2022 using purchasing power parity with Germany as the target currency. All calculations done using CCEMG –EPPI-Centre Cost Converter.10, http://eppi.ioe.ac.uk/costconversion/Default.aspx.

Estimate n. of stroke events (TAVI with CEP vs. TAVI without CEP) based on Kapadia, et al. N Engl J Med 2022; 387:1253-1263 DOI: 10.1056/NEJMoa2204961.*Significant 60% relative risk reduction in disabling stroke observed in PROTECTED TAVR trial.

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.